Ignite Creation Date:
2025-12-24 @ 5:25 PM
Ignite Modification Date:
2025-12-29 @ 2:19 AM
Study NCT ID:
NCT07176650
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-16
First Post:
2025-09-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Sponsor:
Shanghai Henlius Biotech
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-01
First Submit QC Date:
None
Study First Post Date:
2025-09-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-09
Last Update Post Date:
2025-09-16
Last Update Post Date Type:
ESTIMATED